Immunomodulatory Molecule PD-L1 is Expressed on Malignant Plasma Cells and Myeloma-propagating Pre-plasma Cells in the Bone Marrow of Multiple Myeloma Patients

Overview

Journal Blood Cancer J

Date 2015 Mar 10

PMID 25747678

Citations 54

Authors

S Yousef

J Marvin

M Steinbach

A Langemo

T Kovacsovics

M Binder

N Kroger

T Luetkens

D Atanackovic

Affiliations

Soon will be listed here.

Citing Articles

Bacteria Synergized with PD-1 Blockade Enhance Positive Feedback Loop of Cancer Cells-M1 Macrophages-T Cells in Glioma.

Chen Q, Zheng Y, Chen X, Xing Y, Zhang J, Yan X Adv Sci (Weinh). 2024; 11(20):e2308124.

PMID: 38520726 PMC: 11132069. DOI: 10.1002/advs.202308124.

Dissecting molecular mechanisms of immune microenvironment dysfunction in multiple myeloma and precursor conditions.

Moscvin M, Evans B, Bianchi G J Cancer Metastasis Treat. 2024; 9.

PMID: 38213954 PMC: 10783205. DOI: 10.20517/2394-4722.2022.110.

Molecular and immunological mechanisms of clonal evolution in multiple myeloma.

Forster S, Radpour R, Ochsenbein A Front Immunol. 2023; 14:1243997.

PMID: 37744361 PMC: 10516567. DOI: 10.3389/fimmu.2023.1243997.

Therapeutic strategies to enhance immune response induced by multiple myeloma cells.

Liu Z, Yang C, Liu X, Xu X, Zhao X, Fu R Front Immunol. 2023; 14:1169541.

PMID: 37275861 PMC: 10232766. DOI: 10.3389/fimmu.2023.1169541.

TIGIT inhibition and lenalidomide synergistically promote antimyeloma immune responses after stem cell transplantation in mice.

Minnie S, Waltner O, Ensbey K, Olver S, Collinge A, Sester D J Clin Invest. 2022; 133(4).

PMID: 36512425 PMC: 9927935. DOI: 10.1172/JCI157907.

References

Ansell S, Lesokhin A, Borrello I, Halwani A, Scott E, Gutierrez M . PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med. 2014; 372(4):311-9. PMC: 4348009. DOI: 10.1056/NEJMoa1411087. View

Kumar S, Dispenzieri A, Lacy M, Gertz M, Buadi F, Pandey S . Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2013; 28(5):1122-8. PMC: 4000285. DOI: 10.1038/leu.2013.313. View

Rawstron A, Child J, De Tute R, Davies F, Gregory W, Bell S . Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study. J Clin Oncol. 2013; 31(20):2540-7. DOI: 10.1200/JCO.2012.46.2119. View

Tamura H, Ishibashi M, Yamashita T, Tanosaki S, Okuyama N, Kondo A . Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma. Leukemia. 2012; 27(2):464-72. DOI: 10.1038/leu.2012.213. View

Chaidos A, Barnes C, Cowan G, May P, Melo V, Hatjiharissi E . Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma. Blood. 2012; 121(2):318-28. DOI: 10.1182/blood-2012-06-436220. View

Brahmer J, Tykodi S, Chow L, Hwu W, Topalian S, Hwu P . Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012; 366(26):2455-65. PMC: 3563263. DOI: 10.1056/NEJMoa1200694. View

Topalian S, Hodi F, Brahmer J, Gettinger S, Smith D, Mcdermott D . Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366(26):2443-54. PMC: 3544539. DOI: 10.1056/NEJMoa1200690. View

Feyler S, Scott G, Parrish C, Jarmin S, Evans P, Short M . Tumour cell generation of inducible regulatory T-cells in multiple myeloma is contact-dependent and antigen-presenting cell-independent. PLoS One. 2012; 7(5):e35981. PMC: 3362588. DOI: 10.1371/journal.pone.0035981. View

Hallett W, Jing W, Drobyski W, Johnson B . Immunosuppressive effects of multiple myeloma are overcome by PD-L1 blockade. Biol Blood Marrow Transplant. 2011; 17(8):1133-45. DOI: 10.1016/j.bbmt.2011.03.011. View

10.

Rosenblatt J, Glotzbecker B, Mills H, Vasir B, Tzachanis D, Levine J . PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine. J Immunother. 2011; 34(5):409-18. PMC: 3142955. DOI: 10.1097/CJI.0b013e31821ca6ce. View

11.

Palumbo A, Anderson K . Multiple myeloma. N Engl J Med. 2011; 364(11):1046-60. DOI: 10.1056/NEJMra1011442. View

12.

Benson Jr D, Bakan C, Mishra A, Hofmeister C, Efebera Y, Becknell B . The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood. 2010; 116(13):2286-94. PMC: 3490105. DOI: 10.1182/blood-2010-02-271874. View

13.

Keir M, Butte M, Freeman G, Sharpe A . PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008; 26:677-704. PMC: 10637733. DOI: 10.1146/annurev.immunol.26.021607.090331. View

14.

Liu J, Hamrouni A, Wolowiec D, Coiteux V, Kuliczkowski K, Hetuin D . Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood. 2007; 110(1):296-304. DOI: 10.1182/blood-2006-10-051482. View

15.

Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N . Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A. 2002; 99(19):12293-7. PMC: 129438. DOI: 10.1073/pnas.192461099. View